Responses

PDF

Extended report
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Herpes zoster infection risk in patients with rheumatoid arthritis on tumor necrosis factor inhibitors Prabha Ranganathan MD, MS

    Dear Editor,

    We read with interest the study conducted by Galloway and colleagues on the risk of skin and soft tissue infections (SSTI) and herpes zoster (HZ) in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) antagonists versus non-biologic disease-modifying anti-rheumatic drugs (nbDMARDs). (1) This study highlights the occurrence of common infections such as SSTI and more unco...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    TNF antagonists and Shingles: Is Vaccination Advisable?

    Dear Editor,

    We read with interest the report by Galloway et al on the risk of skin and soft tissue infections (including shingles) in patients exposed to TNF antagonists from the BSRBR [1]. In the light of our recently published systematic literature review of the risk of shingles in rheumatoid arthritis (RA) patients, we would like to address several issues raised in the report [2]. The authors state that the inci...

    Show More
    Conflict of Interest:
    None declared.